Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O96013
UPID:
PAK4_HUMAN
Alternative names:
p21-activated kinase 4
Alternative UPACC:
O96013; B4DGG6; Q8N4E1; Q8NCH5; Q8NDE3; Q9BU33; Q9ULS8
Background:
Serine/threonine-protein kinase PAK 4, also known as p21-activated kinase 4, is a pivotal enzyme in cellular signaling. It orchestrates a variety of critical processes including cytoskeleton regulation, cell migration, proliferation, and survival. Activation by growth factor receptors or CDC42 and RAC1 leads to autophosphorylation, influencing several downstream targets such as SSH1, cofilin, LIMK1, ITGB5, ARHGEF2, RHOA, BAD, and RAN. This modulation affects actin filament stability, cell motility, apoptosis, and cell-cycle progression.
Therapeutic significance:
Understanding the role of Serine/threonine-protein kinase PAK 4 could open doors to potential therapeutic strategies.